Q-omics provides the consensus-scored IL21R profile across patient tissues and cancer cell-line models. IL21R expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, IL21R is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, IL21R RNA expression shows 20,945 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight SKCM, KIRC, and LSCC as cancer lineages where IL21R shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IL21R — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IL21R survival associations across molecular data types. IL21R RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IL21R RNA expression–survival associations across cancer types. High IL21R expression shows unfavorable associations in UVM and KIRP, but favorable associations in SKCM, HNSC, LUAD and CESC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for IL21R RNA expression.
This table summarizes IL21R tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for IL21R. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IL21R shows higher tumor expression in KIRC, HNSC, BRCA, STAD, LUAD and THCA. The KIRC box plot shows higher IL21R RNA expression in tumor versus normal tissue (log2 FC = +1.456, t-test p < 0.001).
This table shows molecular features associated with IL21R in patient tissues and cancer cell lines. In patient samples, IL21R shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, IL21R RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and SOFT_TISSUE.
